Clinical Trial

A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 6, 2024 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a study to evaluate the maximum tolerated dose (MTD), dose limiting toxicity (DLT), occurrence of all adverse events (AEs) and serious adverse events (SAEs), pharmacokinetic parameters, pharmacodynamic parameters, immunogenicity, and anti-tumor effects of TQB2029 for injection in Chinese adult subjects with multiple myeloma. The study is divided into Phase Ia and Ib, Phase Ia: dose escalation phase, to evaluate the safety and tolerability of TQB2029 for injection, and determining DLT and MTD; Phase Ib: Dose extension phase, to evaluate the effectiveness of TQB2029 for injection in subjects with multiple myeloma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-20; most recent amendment 2024-12-04.
Status change: Not Yet Recruiting → Recruiting 2024-12-04
Trial Details
NCT Number NCT06700395
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions Multiple Myeloma
Enrollment 136 participants
Start Date 2024-11-28
Primary Completion 2026-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2024-12-06